Onkologic Inc.

Revolutionizing NK Cell Therapy By Re-inventing NK Cell Media. Onkologic is creating a paradigm shift in NK cell media. We are supporting significant advancements in the field of NK cell therapy by reformulating NK cell media products that support enhanced efficacy and potency of NK cellular immunotherapy against cancer. Our media formulations also support other CD56+ immune cells, such as gamma-delta T cells. Created as a spin-off from product development efforts initiated at Enable Life Sciences LLC, Onkologic Inc. offers novel media formulations. Developed under the aegis of an NIH grant, Enable-NK media uniquely combine ingredients, including phytochemical ingredients from plant extracts. Our product portfolio includes Enable-NK media formulations in their ready-to-use versions, as well as 10x concentrate supplement versions (which can be an additive to any starting media of choice). Key Performance Metrics: 30-40% improved cytotoxicity against cancer cells 20-25% reduced cellular exhaustion 2x-3x improved transduction efficiency Up to 90% reduction in serum dependence 35-40% improvement in cryopreservation efficiency Reduction in feeder cell dependence / synergy with feeder cells OVERCOME: Natural Killer (NK) immune cells are difficult to grow, genetically engineer, and preserve (i.e. freeze) outside the human body as cellular immunotherapy. OUTPERFORM: NK cells cultured in Enable-NK media demonstrated enhanced cytotoxic performance against cancer cells, decreased cellular exhaustion, and robust quality parameters. OPTIMIZE: Enable-NK media products offer a range of options for NK cell expansion. Feeder-free expansion of NK cells is supported with and without IL-2. Synergy is also offered by Enable-NK media for feeder cell based expansion of NK cells. A range of suggested protocols are available with the Enable-NK media products available in both non-GMP and GMP manufactured versions. Learn more by reaching us at contact@onkologic.com